Choose a model
Each card values Soleno Therapeutics a different way, shown at our starting inputs. Pick one to see and change how it works.
Set your assumptions
Soleno Therapeutics on earnings: earnings per share grow for a few years, then the stock trades at a normal price-to-earnings multiple.
Years to project
Growth of earnings per share
Earnings per share; not enough history; starts at 5%
Exit P/E
Starts at its industry's median P/E
Your desired return
Margin of safety
More
Your buy price
The expected return is measured from it; starts at today's price
How it's worked out
Today's earnings per share
Diluted EPS of $1.93 as filed, last twelve months, lowered to what operating profit after tax supports (one-off gains left out)
$1.51
Earnings in 2031
Grows 5.0% a year for 5 years
$1.93
Price in 2031
$1.93 × 5.0 P/E
$9.63
Worth today
÷ 1.10^5: your 10% a year, taken back out
$5.98
Fair value
The most you can pay and still earn 10% a year
$5.98
Buy below
Fair value minus your 25% margin of safety
$4.49
Every rule is on the methodology page.
Outcome
What your assumptions give, and the path from today's price.
Fair value
$5.98
Expected return
Set a buy price
Future price, 2031
$9.63
Buy below
$4.49
Projection
Solid blue: the price at each year end. Dashed blue: from today's price to the 2031 price. Green: from the fair value, rising at your 10% a year to the same end point; buy at or below it and you earn at least that. Every rule is on the methodology page. A model, not a forecast or advice.
Build your own intrinsic value for Soleno Therapeutics Inc. Start from three cases based on the company's own filings, then change any number to match your view.
Conservative
$66.32
Buy below $49.74 for a 25% safety margin
Your assumptions
Base
$110.86
Buy below $83.14 for a 25% safety margin
Your assumptions
Optimistic
$208.16
Buy below $156.12 for a 25% safety margin
Your assumptions
Where today's price sits
The three intrinsic values, without a price to compare them with.
Base free cash flow
$105M
Trailing twelve months
Historical FCF CAGR
+125.6%
Across 6 reported periods
Market implies
–
Needs a comparable price
Terminal value share
69%
Of the base case valuation
Growth needed to justify today's price
No growth rate in the tested range reproduces today's price at these assumptions.
Curve holds terminal growth at 2.5%, years 6 to 10 at half the first-stage rate, and applies no safety margin.
Free cash flow history
The most recent period is the base every projection starts from. Compounded, that history is +125.6% a year.
Soleno Therapeutics (SLNO) intrinsic value and fair value
The calculator grows one of Soleno Therapeutics's per-share figures (earnings, free cash flow, revenue, book value or dividends) for a few years, puts an exit multiple on it, and discounts the result back at the yearly return you want. The answers below use its starting inputs for SLNO; this is analysis, not investment advice.
Frequently asked
What is Soleno Therapeutics's (SLNO) intrinsic value?+
With Intrinsiqq's starting inputs, Soleno Therapeutics's fair value is about $5.98 a share, based on its earnings per share. That assumes earnings per share of $1.51 grows about 5.0% a year for 5 years, the stock then trades at 5.0 times earnings, and you want a 10.0% yearly return. On its other figures: free cash flow $28.85, revenue $9.26. Every input can be changed on the page; the result is a model, not a forecast.
What growth does the Soleno Therapeutics valuation assume?+
Earnings per share grows about 5.0% a year to start, a default, because there is too little history. The exit multiple starts at its industry's median.
What is a good margin of safety for Soleno Therapeutics?+
A margin of safety is the cushion you want below the fair value before buying, in case the inputs are wrong. The calculator uses 25%, which puts the buy-below price at $4.49. Less predictable businesses deserve a wider cushion, or a higher desired return.
SourceFair value computed from the 10-Q filed 30 Apr 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 3 Sept 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with SLNO
Spot a number that looks wrong? Check it in SLNO's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SLNO
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.